Eli Lilly Pauses COVID-19 Antibody Trial

>>Follow Matzav On Whatsapp!<<

Enrollment for Eli Lilly’s late-stage trial of its monoclonal antibody treatment is being put on hold over potential safety concerns following a recommendation from U.S. health regulators.

“Safety is of the utmost importance to Lilly,” an Eli Lilly spokesperson told FOX Business in a statement Tuesday. “We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment.”

The trial is used to test the safety and efficacy of Eli Lilly’s antibody treatment for hospitalized patients battling  COVID-19, and is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Read more at Fox Business.



  1. Until now doctors told us that it’s a positive thing to have antibodies as it’s a sign that you already had “coronavirus”. (As if people weren’t sick more than once with corona nonsense throughout these months.) Now suddenly they’re treating antibodies? What’s going on?


Please enter your comment!
Please enter your name here